EP Patent

EP2303025A1 — Methods for treating visceral fat conditions

Assigned to Orexigen Therapeutics Inc · Expires 2011-04-06 · 15y expired

What this patent protects

Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.

USPTO Abstract

Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.

Drugs covered by this patent

Patent Metadata

Patent number: EP2303025A1
Jurisdiction: EP
Classification: —
Expires: 2011-04-06
Drug substance claim: No
Drug product claim: No
Assignee: Orexigen Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.